• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Albemarle Reports Fourth Quarter and Full Year 2025 Results

    2/11/26 4:15:00 PM ET
    $ALB
    Major Chemicals
    Industrials
    Get the next $ALB alert in real time by email

    CHARLOTTE, N.C., Feb. 11, 2026 /PRNewswire/ -- Albemarle Corporation (NYSE:ALB), a global leader in providing essential elements for mobility, energy, connectivity and health, today announced its results for the fourth quarter and full year ended December 31, 2025.

    Albemarle Corp. Logo. (PRNewsFoto/Albemarle Corporation)

    Fourth Quarter and Full Year 2025 Results and Highlights

    (Unless otherwise stated, all percentage changes represent year-over-year comparisons)

    • Fourth quarter net sales of $1.4 billion, up 16%; volume up 12%, including gains in all segments led by Energy Storage (up 17%) and Ketjen (up 13%).
    • Fourth quarter net loss of ($414) million, or ($3.87) per diluted share, includes tax-related items and the write-down of assets in relation to the expected Ketjen transaction value; adjusted diluted loss per share of ($0.53)(a).
    • Fourth quarter adjusted EBITDA(a) of $269 million, up 7%, led by Energy Storage (+25%) and Ketjen (+39%).
    • Full year cash from operations of $1.3 billion, representing more than 100% operating cash flow conversion(b), driven primarily by cost and productivity improvements, working capital management, and a customer pre-payment received in January 2025.
    • Free cash flow of $692 million(a) reflects strong operating cash flow conversion and significantly lower capital expenditures of $590 million (down 65% year-over-year).
    • Achieved approximately $450 million of cost and productivity improvements, exceeding the initial target of $300 to $400 million.
    • Closed sale of 50% stake in the Eurecat joint venture for $123 million cash in January 2026; on track to close sale of controlling stake in Ketjen in Q1 2026.
    • Introducing full-year 2026 outlook considerations, including ranges based on updated lithium market price scenarios:
      • New scenarios highlight improved lithium market conditions and operational performance.
      • Full-year 2026 capital expenditures expected to be approximately flat year-over-year, reflecting consistent sustaining capital, Ketjen divestiture and targeted growth capital focused on productivity gains and resource development.
      • Meaningful free cash flow generation assuming recent higher lithium prices.

    (a)

    See Non-GAAP Reconciliations for further details.

    (b)

    Defined as Operating Cash Flow divided by Adj. EBITDA, which is a non-GAAP measure. See Non-GAAP Reconciliations for further details.

    "Our results for the fourth quarter and full year 2025 are a testament to our team's focus on execution amid dynamic market conditions. Albemarle achieved year-over-year sales growth of more than 15% in the fourth quarter, as well as strong full-year cash flow generation and significant cost and productivity improvements," said Kent Masters, Chairman and CEO. "The steps we have taken to optimize our asset portfolio, reduce costs and strengthen our financial flexibility have improved our competitive position. Even as market conditions improve, we continue to drive cost reduction and productivity actions to enable long-term growth, powered by our world-class resources."

    Fourth Quarter 2025 Results

    In millions, except per share amounts

    Q4 2025



    Q4 2024



    $ Change



    % Change(c)

    Net sales

    $   1,428.0



    $   1,231.7



    $       196.3



    15.9 %

    Net (loss) income attributable to Albemarle Corporation

    $     (414.2)



    $        75.3



    $      (489.5)



    NM

    Adjusted EBITDA(a)

    $      268.7



    $      250.7



    $         18.0



    7.2 %

    Diluted (loss) earnings per share attributable to common shareholders

    $       (3.87)



    $        0.29



    $        (4.16)



    NM

       Non-operating pension and OPEB items(a)

    0.15



    (0.07)









       Non-recurring and other unusual items(a)

    3.19



    (1.31)









    Adjusted diluted loss per share attributable to common shareholders(a)(b)

    $      (0.53)



    $      (1.09)



    $         0.56



    51.4 %



    (a)

    See Non-GAAP Reconciliations for further details.

    (b)

    Totals may not add due to rounding.

    (c)

    Certain percentage changes are considered not meaningful ("NM")

    Net sales for the fourth quarter of 2025 were $1.4 billion compared to $1.2 billion for the prior-year quarter, an increase of 16%, driven primarily by higher volumes in Energy Storage (+17%) and Ketjen (+13%) and higher pricing in Energy Storage. Net loss attributable to Albemarle of $414 million increased year-over-year by $490 million primarily due to tax-related items and the write-down of assets in relation to the expected Ketjen transaction value. Excluding these one-time items, adjusted net loss improved year-over-year. Adjusted EBITDA of $269 million increased by $18 million from the prior-year quarter primarily due to higher pricing in Energy Storage and higher volumes in Ketjen.

    The effective income tax rate for the fourth quarter of 2025 was (55.2)%, compared to 13.8% in the same period of 2024. On an adjusted basis, the effective income tax rates were 561.1% and 446.9% for the fourth quarters of 2025 and 2024, respectively, with the increase primarily due to recording a valuation allowance on the entirety of U.S. deferred tax assets in the fourth quarter of 2025, as well as changes in geographic income mix, including the impact of previously recorded valuation allowances in Australia and China.

    Energy Storage Results

    In millions

    Q4 2025



    Q4 2024



    $ Change



    % Change

    Net Sales

    $           759.1



    $           616.8



    $           142.2



    23.1 %

    Adjusted EBITDA

    $           167.1



    $           133.7



    $             33.4



    25.0 %

    Energy Storage net sales for the fourth quarter of 2025 were $759 million, an increase of $142 million, or 23%, primarily due to higher volumes (+17%) and pricing (+6%). Adjusted EBITDA of $167 million increased $33 million, or 25%, primarily due to higher pricing and cost and productivity improvements.

    Energy Storage adjusted EBITDA for the full year 2025 was $697 million, down 8% versus the year prior, as higher sales volumes and cost and productivity improvements mostly offset lower lithium market pricing.

    Specialties Results

    In millions

    Q4 2025



    Q4 2024



    $ Change



    % Change

    Net Sales

    $           348.9



    $           332.9



    $             16.0



    4.8 %

    Adjusted EBITDA

    $             68.6



    $             72.9



    $              (4.3)



    (5.9) %

    Specialties net sales for the fourth quarter of 2025 were $349 million, an increase of $16 million, or 5%, primarily due to higher volumes (+2%) and pricing (+1%). Adjusted EBITDA of $69 million decreased $4 million versus the year-ago quarter primarily due to margin compression in lithium specialties, down from 2024 highs.

    Specialties adjusted EBITDA for the full year 2025 was $276 million, increasing 21% year-over-year, as higher volumes and cost and productivity improvements more than offset lower pricing.

    Ketjen Results

    In millions

    Q4 2025



    Q4 2024



    $ Change



    % Change

    Net Sales

    $           320.1



    $           281.9



    $             38.1



    13.5 %

    Adjusted EBITDA

    $             49.7



    $             35.8



    $             13.9



    38.8 %

    Ketjen net sales for the fourth quarter of 2025 were $320 million, up 14% compared to the prior-year quarter primarily due to higher fluidized catalytic cracking (FCC) volumes and timing of Clean Fuels technology (CFT) sales. Adjusted EBITDA of $50 million increased $14 million, driven by favorable product mix and lower input costs.

    Ketjen adjusted EBITDA for the full year 2025 was $150 million, an increase of 15%, primarily due to increased FCC volumes.

    2026 Outlook Considerations

    Total Corporate Outlook Considerations

    The table below reflects expected outcomes for the total company based on recently observed lithium market price scenarios. Outlook ranges for each scenario are based on variation in sales volume and product mix. Energy Storage production volumes are expected to increase year-over-year. Sales volumes are expected to be approximately flat following inventory drawdowns that occurred in 2025. All three scenarios assume flat market pricing flowing through Energy Storage's current contract book which includes approximately 40% of salts volume on long-term agreements. Scenarios also assume that spodumene pricing averages 10% of the lithium carbonate equivalent (LCE) price, while other costs are assumed to be constant.



    Total Corporate FY 2026E

    Including Energy Storage Scenarios

    Observed market price case(a)

    FY 2025 avg.

    Jan. 2026 avg.

    2021-2025 avg.

    Average lithium market price ($/kg LCE)(a)

    ~$10

    ~$20

    ~$30

    Net sales

    $4.1 - $4.3 billion

    $5.7 - $6.0 billion

    $7.5 - $7.8 billion

    Adjusted EBITDA(b)

    $0.9 - $1.0 billion

    $2.4 - $2.6 billion

    $4.2 - $4.4 billion



    (a)

    Price represents blend of relevant market pricing including spot and regional indices for the periods referenced.

    (b)

    The Company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable financial measures

    calculated and reported in accordance with GAAP, as the company is unable to estimate significant non-recurring or unusual items without unreasonable effort.

    See "Additional information regarding Non-GAAP Measures" for more information.

    Energy Storage Market Price Scenarios



    Energy Storage FY 2026E

    Observed market price case(a)

    FY 2025 avg.

    Jan. 2026 avg.

    2021-2025 avg.

    Average lithium market price ($/kg LCE)(a)

    ~$10

    ~$20

    ~$30

    Net sales

    $2.5 - $2.6 billion

    $4.0 - $4.2 billion

    $5.9 - $6.1 billion

    Adjusted EBITDA

    $0.7 - $0.8 billion

    $2.1 - $2.3 billion

    $3.9 - $4.1 billion

    Equity in net income of unconsolidated investments (net of tax)(b)

    $0.2 - $0.3 billion

    $0.6 - $0.7 billion

    $1.0 - $1.1 billion







    (a)

    Price represents blend of relevant market pricing including spot and regional indices for the periods referenced.

    (b)

    Included in adjusted EBITDA on a pre-tax basis.

    Specialties Outlook Considerations

    Specialties outlook reflects modest volume growth in key end markets led by semiconductor and pharmaceutical partially offset by expected softness in automotive, building and construction and oil and gas.

    Net sales are expected to be flat to down and adjusted EBITDA is expected to be lower in 2026 compared to 2025 due, in part, to lithium specialties pricing, which has adjusted lower from the previous peak, and reduced demand for clear brine fluids due to weakness in oil and gas markets. Production volume in 2026 is expected to be impacted by a major flooding event that occurred at our Jordan Bromine Company (JBC) joint venture in January 2026. JBC has since returned to full operating rates.



    Segment FY 2026E

    Specialties net sales

    $1.2 - $1.4 billion

    Specialties adjusted EBITDA

    $170 - $230 million

    Other Corporate Outlook Considerations

    Following the sale of a controlling stake in Ketjen, which is expected to close in the first quarter of 2026, the refining catalyst business earnings will be classified as equity income and included in Corporate, as will the results of the retained Performance Catalyst Solutions (PCS) business. The EBITDA and equity income contributions from these are expected to be immaterial post transaction.

    Albemarle expects its 2026 capital expenditures to be roughly flat compared to 2025, in the range of $550 million to $600 million.



    Other Corporate FY 2026E

    Capital expenditures

    $550 - $600 million

    Depreciation and amortization

    $660 - $680 million

    Adjusted effective tax rate(a)

    (50%) - 30%

    Corporate adjusted EBITDA (incl. FX, Ketjen equity income & PCS)

    ($20) - $20 million

    Interest and financing expenses

    $150 - $170 million

    Weighted-average common shares outstanding (diluted)

    ~118 million



    (a)

    Adjusted effective tax rate dependent on lithium market prices and geographic income mix

    Cash Flow and Capital Deployment

    Cash from operations of $1.3 billion for the year ended December 31, 2025 increased $594 million compared to the prior-year period due to cost and productivity improvements, cash management actions, including inventory reductions, and a customer prepayment received in January. Capital expenditures of $590 million were in-line with the company's most recent outlook and decreased by $1.1 billion versus the prior-year period, reflecting the impact of decisions that stopped or slowed spending and the completion of capacity expansions in Energy Storage and Specialties.

    Balance Sheet and Liquidity

    As of December 31, 2025, Albemarle had estimated liquidity of approximately $3.2 billion, including $1.6 billion of cash and equivalents, $1.5 billion available under its revolver and $105 million available on other credit lines. Total debt was $3.2 billion, representing a net debt to adjusted EBITDA ratio (as defined in our credit agreement) of approximately 2.0 times.

    Earnings Call

    Date:

    Thurs., Feb. 12, 2026

    Time:

    8:00 AM Eastern time

    Dial-in (U.S.):

     +1 800-590-8290

    Dial-in (International):

     +1 240-690-8800

    Passcode:

    ALBQ4

    The company's earnings presentation and supporting material are available on Albemarle's website at https://investors.albemarle.com.

    About Albemarle

    Albemarle Corporation (NYSE:ALB) leads the world in transforming essential resources into critical ingredients for mobility, energy, connectivity, and health. We partner to pioneer new ways to move, power, connect and protect with people and planet in mind. A reliable and high-quality global supply of lithium and bromine allow us to deliver advanced solutions for our customers. Learn more about how the people of Albemarle are enabling a more resilient world at Albemarle.com.

    Albemarle regularly posts information to Albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, non-GAAP reconciliations, Securities and Exchange Commission ("SEC") filings and other information regarding the company, its businesses and the markets it serves.

    Forward-Looking Statements

    This press release contains statements concerning our expectations, anticipations and beliefs regarding the future, which constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties, often contain words such as "ambition," "anticipate," "believe," "estimate," "expect," "goal," "guidance," "intend," "may," "outlook," "scenario," "should," "would," and "will". Forward-looking statements may include statements regarding: our 2026 company and segment outlooks, including expected market pricing of lithium carbonate equivalent and spodumene and other underlying assumptions and outlook considerations; planned sale of a controlling stake in Ketjen and the amount of the proceeds for the controlling stake in Ketjen and our interest in the Eurecat JV; timing for completion of both transactions, including obtaining regulatory approvals and meeting other closing conditions; expectations regarding use of proceeds from the both transactions; expected capital expenditure amounts and the corresponding impact on cash flow; expected impact of tariffs and other trade restrictions; plans and expectations regarding other projects and activities, cost reductions and accounting charges, and all other information relating to matters that are not historical facts. Factors that could cause Albemarle's actual results to differ materially from the outlook expressed or implied in any forward-looking statement include: changes in economic and business conditions; changes in trade policies and tariffs; financial and operating performance of customers; timing and magnitude of customer orders; fluctuations in lithium and spodumene market prices; production volume shortfalls; increased competition; changes in product demand; availability and cost of raw materials and energy; technological change and development; fluctuations in foreign currencies; changes in laws and government regulation; regulatory actions, proceedings, claims or litigation; cyber-security breaches, terrorist attacks, industrial accidents or natural disasters; risks related to the integration of artificial intelligence technologies into our operations; geopolitical conflicts and political unrest; our ability to retain key personnel and attract new skilled personnel; changes in inflation or interest rates; volatility in the debt and equity markets; acquisition and divestiture transactions; timing and success of projects; performance of Albemarle's partners in joint ventures and other projects; changes in credit ratings; and the other factors detailed from time to time in the reports Albemarle files with the SEC, including those described under "Risk Factors" in Albemarle's most recent Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q, which are filed with the SEC and available on the investor section of Albemarle's website (investors.albemarle.com) and on the SEC's website at www.sec.gov. These forward-looking statements speak only as of the date of this press release. Albemarle assumes no obligation to provide any revisions to any forward-looking statements should circumstances change, except as otherwise required by securities and other applicable laws.

     

    Albemarle Corporation and Subsidiaries

    Consolidated Statements of (Loss) Income

    (In Thousands Except Per Share Amounts) (Unaudited)





    Three Months Ended



    Year Ended



    December 31,



    December 31,



    2025



    2024



    2025



    2024

    Net sales

    $ 1,428,031



    $ 1,231,713



    $ 5,142,733



    $  5,377,526

    Cost of goods sold

    1,230,097



    1,093,500



    4,474,014



    5,314,987

    Gross profit

    197,934



    138,213



    668,719



    62,539

    Selling, general and administrative expenses

    155,500



    135,996



    550,036



    618,048

    Goodwill impairment charges

    —



    —



    181,070



    —

    Long-lived asset impairment charges

    245,600



    —



    245,600



    —

    Restructuring charges and asset write-offs

    2,039



    (22,206)



    7,699



    1,134,316

    Research and development expenses

    12,181



    20,021



    51,398



    86,720

    Operating (loss) profit

    (217,386)



    4,402



    (367,084)



    (1,776,545)

    Interest and financing expenses

    (57,776)



    (44,703)



    (207,651)



    (165,619)

    Other (expenses) income, net

    (9,828)



    117,028



    22,662



    178,339

    (Loss) income before income taxes and equity in net income of unconsolidated investments

    (284,990)



    76,727



    (552,073)



    (1,763,825)

    Income tax expense

    157,330



    10,613



    156,881



    87,085

    (Loss) income before equity in net income of unconsolidated investments

    (442,320)



    66,114



    (708,954)



    (1,850,910)

    Equity in net income of unconsolidated investments (net of tax)

    40,560



    18,997



    243,744



    715,433

    Net (loss) income

    (401,760)



    85,111



    (465,210)



    (1,135,477)

    Net income attributable to noncontrolling interests

    (12,419)



    (9,818)



    (45,418)



    (43,972)

    Net (loss) income attributable to Albemarle Corporation

    (414,179)



    75,293



    (510,628)



    (1,179,449)

    Mandatory convertible preferred stock dividends

    (41,687)



    (41,688)



    (166,750)



    (136,647)

    Net (loss) income attributable to Albemarle Corporation common shareholders

    $  (455,866)



    $     33,605



    $  (677,378)



    $  (1,316,096)

    Basic (loss) earnings per share attributable to common shareholders

    $       (3.87)



    $         0.29



    $        (5.76)



    $       (11.20)

    Diluted (loss) earnings per share attributable to common shareholders

    $       (3.87)



    $         0.29



    $        (5.76)



    $       (11.20)

















    Weighted-average common shares outstanding – basic

    117,701



    117,549



    117,664



    117,516

    Weighted-average common shares outstanding – diluted

    117,701



    117,723



    117,664



    117,516

     

    Albemarle Corporation and Subsidiaries

    Condensed Consolidated Balance Sheets

    (In Thousands) (Unaudited)





    December 31,



    December 31,



    2025



    2024

    ASSETS







    Current assets:







      Cash and cash equivalents

    $        1,618,001



    $        1,192,230

      Trade accounts receivable

    593,502



    742,201

      Other accounts receivable

    105,110



    238,384

      Inventories

    1,179,271



    1,502,531

      Other current assets

    140,440



    166,916

      Current assets held for sale

    371,815



    —

    Total current assets

    4,008,139



    3,842,262

    Property, plant and equipment, at cost

    11,768,840



    12,523,368

    Less accumulated depreciation and amortization

    3,156,429



    3,191,898

    Net property, plant and equipment

    8,612,411



    9,331,470

    Investments

    900,926



    1,117,739

    Other assets

    647,185



    504,711

    Goodwill

    1,499,657



    1,582,714

    Other intangibles, net of amortization

    214,233



    230,753

    Noncurrent assets held for sale

    491,660



    —

    Total assets

    $      16,374,211



    $      16,609,649

    LIABILITIES AND EQUITY







    Current liabilities:







      Accounts payable to third parties

    $           779,160



    $           793,455

      Accounts payable to related parties

    134,369



    150,432

      Accrued expenses

    521,831



    467,997

      Current portion of long-term debt

    74,077



    398,023

      Dividends payable

    61,387



    61,282

      Income taxes payable

    35,467



    95,275

     Current liabilities held for sale

    191,753



    —

    Total current liabilities

    1,798,044



    1,966,464

    Long-term debt

    3,119,464



    3,118,142

    Postretirement benefits

    44,744



    31,930

    Pension benefits

    117,361



    116,192

    Other noncurrent liabilities

    1,084,892



    819,204

    Deferred income taxes

    368,275



    358,029

    Noncurrent liabilities held for sale

    59,970



    —

    Commitments and contingencies







    Equity:







    Albemarle Corporation shareholders' equity:







      Common stock

    1,178



    1,176

      Mandatory convertible preferred stock

    2,235,105



    2,235,105

      Additional paid-in-capital

    3,018,213



    2,985,606

      Accumulated other comprehensive loss

    (334,807)



    (742,062)

      Retained earnings

    4,613,676



    5,481,692

    Total Albemarle Corporation shareholders' equity

    9,533,365



    9,961,517

    Noncontrolling interests

    248,096



    238,171

    Total equity

    9,781,461



    10,199,688

    Total liabilities and equity

    $      16,374,211



    $      16,609,649

     

    Albemarle Corporation and Subsidiaries

    Selected Consolidated Cash Flow Data

    (In Thousands) (Unaudited)





    Year Ended



    December 31,



    2025



    2024

    Cash and cash equivalents at beginning of year

    $   1,192,230



    $     889,900

    Cash flows from operating activities:







    Net loss

    (465,210)



    (1,135,477)

    Adjustments to reconcile net loss to cash flows from operating activities:







    Depreciation and amortization

    658,678



    588,638

    Non-cash goodwill impairment charges

    181,070



    —

    Non-cash long-lived asset impairment charges

    245,600



    —

    Non-cash restructuring and asset write-offs

    —



    1,013,444

    Stock-based compensation and other

    40,271



    32,141

    Equity in net income of unconsolidated investments (net of tax)

    (243,744)



    (715,433)

    Dividends received from unconsolidated investments and nonmarketable securities

    93,739



    358,933

    Pension and postretirement expense (benefit)

    23,377



    (5,274)

    Pension and postretirement contributions

    (20,441)



    (19,379)

    Realized loss on investments in marketable securities

    —



    33,746

    Unrealized (gain) loss on investments in marketable securities

    (14,088)



    30,073

    Loss on early extinguishment of debt

    7,471



    —

    Deferred income taxes

    81,169



    (230,406)

    Changes in current assets and liabilities, net of effects of acquisitions and divestitures:







    Decrease in accounts receivable

    47,315



    555,218

    Decrease in inventories

    212,351



    1,055,036

    Decrease in other current assets

    4,027



    244,987

    Increase (decrease) in accounts payable to third parties

    144,208



    (462,839)

    (Decrease) in accounts payable to related parties

    (16,063)



    (399,398)

    (Decrease) in accrued expenses and income taxes payable

    (36,753)



    (140,099)

    Noncurrent liability changes and other, net

    339,290



    (116,035)

    Net cash provided by operating activities

    1,282,267



    687,876

    Cash flows from investing activities:







    Capital expenditures

    (589,801)



    (1,680,529)

    Proceeds from sale of property and equipment

    32,812



    29,102

    Proceeds from sale of investments

    290,908



    —

    Proceeds (payments) from settlement of foreign currency forward contracts, net

    114,236



    (15,595)

    Sales of marketable securities, net

    6,077



    82,520

    Investments in equity investments and nonmarketable securities

    (239)



    (270)

    Net cash used in investing activities

    (146,007)



    (1,584,772)

    Cash flows from financing activities:







    Proceeds from issuance of mandatory convertible preferred stock

    —



    2,236,750

    Proceeds from borrowings of long-term debt and credit agreements

    56,728



    112,439

    Repayments of long-term debt and credit agreements

    (505,736)



    (112,439)

    Other repayments,  net

    (5,657)



    (631,834)

    Dividends paid to common shareholders

    (190,530)



    (188,530)

    Dividends paid to mandatory convertible preferred shareholders

    (166,750)



    (122,746)

    Dividends paid to noncontrolling interests

    (18,169)



    (37,194)

    Proceeds from exercise of stock options

    3,240



    374

    Withholding taxes paid on stock-based compensation award distributions

    (7,258)



    (11,891)

    Other

    (55)



    (3,194)

    Net cash (used in) provided by financing activities

    (834,187)



    1,241,735

    Net effect of foreign exchange on cash and cash equivalents

    123,698



    (42,509)

    Increase in cash and cash equivalents

    425,771



    302,330

    Cash and cash equivalents at end of period

    $   1,618,001



    $   1,192,230

     

    Albemarle Corporation and Subsidiaries

    Consolidated Summary of Segment Results

    (In Thousands) (Unaudited) 





    Three Months Ended



    Year Ended



    December 31,



    December 31,



    2025



    2024



    2025



    2024

    Net sales:















    Energy Storage

    $   759,059



    $   616,822



    $ 2,710,035



    $ 3,015,121

    Specialties

    348,901



    332,942



    1,366,435



    1,325,983

    Ketjen

    320,071



    281,949



    1,066,263



    1,036,422

    Total net sales

    $ 1,428,031



    $ 1,231,713



    $ 5,142,733



    $ 5,377,526

















    Adjusted EBITDA:















    Energy Storage

    $   167,058



    $   133,678



    $   697,215



    $   757,540

    Specialties

    68,552



    72,875



    275,739



    228,504

    Ketjen

    49,677



    35,778



    150,398



    131,066

      Total segment adjusted EBITDA

    285,287



    242,331



    1,123,352



    1,117,110

    Corporate

    (16,543)



    8,353



    (25,359)



    22,668

    Total adjusted EBITDA

    $   268,744



    $   250,684



    $ 1,097,993



    $ 1,139,778



    See accompanying non-GAAP reconciliations below.

    Additional Information regarding Non-GAAP Measures

    It should be noted that adjusted net (loss) income attributable to Albemarle Corporation, adjusted net loss attributable to Albemarle Corporation common shareholders, adjusted diluted loss per share attributable to common shareholders, non-operating pension and other post-employment benefit ("OPEB") items per diluted share, non-recurring and other unusual items per diluted share, adjusted effective income tax rates, EBITDA, adjusted EBITDA (on a consolidated basis), EBITDA margin and adjusted EBITDA margin, operating cash flow conversion, and free cash flow are financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in the United States, or GAAP. These non-GAAP measures should not be considered as alternatives to Net (loss) income attributable to Albemarle Corporation ("earnings") or other comparable measures calculated and reported in accordance with GAAP. These measures are presented here to provide additional useful measurements to review the company's operations, provide transparency to investors and enable period-to-period comparability of financial performance. The company's chief operating decision maker uses these measures to assess the ongoing performance of the company and its segments, as well as for business and enterprise planning purposes.

    A description of other non-GAAP financial measures that Albemarle uses to evaluate its operations and financial performance, and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP can be found on the following pages of this press release, which is also available on Albemarle's website at https://investors.albemarle.com. The company does not provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, as the company is unable to estimate significant non-recurring or unusual items without unreasonable effort. The amounts and timing of these items are uncertain and could be material to the company's results calculated in accordance with GAAP.

    ALBEMARLE CORPORATION AND SUBSIDIARIES

    Non-GAAP Reconciliations

    (Unaudited)

    See below for a reconciliation of adjusted net (loss) income attributable to Albemarle Corporation, adjusted net loss attributable to Albemarle Corporation common shareholders, EBITDA and adjusted EBITDA (on a consolidated basis), which are non-GAAP financial measures, to Net (loss) income attributable to Albemarle Corporation ("earnings"), the most directly comparable financial measure calculated and reported in accordance with GAAP. Adjusted net loss attributable to Albemarle Corporation is defined as net loss attributable to Albemarle Corporation before the non-recurring, other unusual and non-operating pension and other post-employment benefit (OPEB) items as listed below. The non-recurring and unusual items may include acquisition and integration related costs, gains or losses on sales of businesses, restructuring charges, facility divestiture charges, certain litigation and arbitration costs and charges, and other significant non-recurring items. Adjusted net loss attributable to Albemarle Corporation common stockholders is defined as adjusted net loss attributable to Albemarle Corporation after mandatory convertible preferred stock dividends. EBITDA is defined as net (loss) income attributable to Albemarle Corporation before interest and financing expenses, income tax expense, and depreciation and amortization. Adjusted EBITDA is defined as EBITDA plus or minus the proportionate share of Windfield Holdings income tax expense, non-recurring, other unusual and non-operating pension and OPEB items as listed below.

     



    Three Months Ended



    Year Ended



    December 31,



    December 31,



    2025



    2024



    2025



    2024

    In thousands, except percentages and per

    share amounts

    $



    % of

    net

    sales



    $



    % of

    net

    sales



    $



    % of

    net

    sales



    $



    % of

    net

    sales

    Net (loss) income attributable to Albemarle

    Corporation

    $  (414,179)







    $     75,293







    $  (510,628)







    $  (1,179,449)





    Add back:































    Non-operating pension and OPEB items

    (net of tax)

    18,181







    (8,014)







    18,664







    (9,045)





    Non-recurring and other unusual items

    (net of tax)

    375,554







    (153,490)







    566,087







    1,049,823





    Adjusted net (loss) income attributable to

    Albemarle Corporation

    $    (20,444)







    $    (86,211)







    $     74,123







    $  (138,671)





    Mandatory convertible preferred

    stock dividends

    (41,687)







    (41,688)







    (166,750)







    (136,647)





    Adjusted net loss attributable to

    Albemarle Corporation common shareholders

    $    (62,131)







    $  (127,899)







    $    (92,627)







    $  (275,318)





































    Adjusted diluted loss per share attributable to

    common shareholders

    $        (0.53)







    $        (1.09)







    $        (0.79)







    $        (2.34)





































    Adjusted weighted-average common shares

    outstanding – diluted

    117,701







    117,549







    117,664







    117,516





































    Net (loss) income attributable to

    Albemarle Corporation

    $  (414,179)



    (29.0) %



    $     75,293



    6.1 %



    $  (510,628)



    (9.9) %



    $  (1,179,449)



    (21.9) %

    Add back:































    Interest and financing expenses

    57,776



    4.0 %



    44,703



    3.6 %



    207,651



    4.0 %



    165,619



    3.1 %

    Income tax expense

    157,330



    11.0 %



    10,613



    0.9 %



    156,881



    3.1 %



    87,085



    1.6 %

    Depreciation and amortization

    163,710



    11.5 %



    163,106



    13.2 %



    658,678



    12.8 %



    588,638



    10.9 %

    EBITDA

    (35,363)



    (2.5) %



    293,715



    23.8 %



    512,582



    10.0 %



    (338,107)



    (6.3) %

    Proportionate share of Windfield income

    tax expense

    16,050



    1.1 %



    6,201



    0.5 %



    94,549



    1.8 %



    299,193



    5.6 %

    Non-operating pension and OPEB items

    16,732



    1.2 %



    (10,342)



    (0.8) %



    17,710



    0.3 %



    (11,335)



    (0.2) %

    Non-recurring and other unusual items

    271,325



    19.0 %



    (38,890)



    (3.2) %



    473,152



    9.2 %



    1,190,027



    22.1 %

    Adjusted EBITDA

    $    268,744



    18.8 %



    $    250,684



    20.4 %



    $ 1,097,993



    21.4 %



    $ 1,139,778



    21.2 %

































    Net sales

    $ 1,428,031







    $ 1,231,713







    $ 5,142,733







    $ 5,377,526





    Non-operating pension and OPEB items, consisting of mark-to-market actuarial gains/losses, settlements/curtailments, interest cost and expected return on assets, are not allocated to Albemarle's operating segments and are included in the Corporate category. In addition, the company believes that these components of pension cost are mainly driven by market performance, and the company manages these separately from the operational performance of the company's businesses. In accordance with GAAP, these non-operating pension and OPEB items are included in Other (expenses) income, net. Non-operating pension and OPEB items were as follows (in thousands):



    Three Months Ended



    Year Ended



    December 31,



    December 31,



    2025



    2024



    2025



    2024

    MTM actuarial loss (gain)

    $     17,246



    $     (9,831)



    $     17,246



    $      (9,831)

    Interest cost

    8,717



    8,696



    35,427



    34,225

    Expected return on assets

    (9,231)



    (9,207)



    (34,963)



    (35,729)

    Total

    $     16,732



    $    (10,342)



    $     17,710



    $    (11,335)

    In addition to the non-operating pension and OPEB items disclosed above, the company has identified certain other items and excluded them from Albemarle's adjusted net (loss) income calculation for the periods presented. A listing of these items, as well as a detailed description of each follows below (per diluted share):



    Three Months Ended



    Year Ended



    December 31,



    December 31,



    2025



    2024



    2025



    2024

    Restructuring charges and asset write-offs(1)

    $         0.02



    $       (0.21)



    $         0.04



    $         9.77

    Goodwill impairment charges(2)

    0.04



    —



    1.54



    —

    Long-lived asset impairment charges(3)

    2.09



    —



    2.09



    —

    Acquisition and integration related costs(4)

    0.04



    0.01



    0.07



    0.04

    (Gain) loss in fair value of public equity securities(5)

    (0.07)



    0.03



    (0.09)



    0.53

    Loss on extinguishment of debt(6)

    0.06



    —



    0.06



    —

    Other(7)

    0.28



    (0.19)



    0.35



    (0.42)

    Tax related items(8)

    0.73



    (0.95)



    0.75



    (1.00)

    Total non-recurring and other unusual items

    $         3.19



    $       (1.31)



    $         4.81



    $         8.92







    (1)



    The Company took several actions during 2024 as part of a broader effort that are focused on preserving its world-class resource advantages, optimizing its global conversion network, improving the Company's cost competitiveness and efficiency, reducing capital intensity and enhancing the Company's financial flexibility. Those actions included stopping construction of Kemerton Trains 3 and 4, as well as certain other capital projects, placing Kemerton Train 2 in care and maintenance and transitioning the Company's operating structure to a fully integrated functional model (excluding Ketjen). Additionally, as part of this restructuring plan, we placed the Chengdu, China conversion plant into care and maintenance during the first half of 2025. As a result, the Company recorded restructuring and asset write-off charges of $2.0 million and $7.7 million in Restructuring charges and asset write-offs for the three months and year ended December 31, 2025, respectively, and a loss of $0.1 million and $0.2 million in Other (expenses) income, net for the three months and year ended December 31, 2025, respectively. Due to the impact of the valuation allowances, this resulted in total after-tax gains of $2.2 million and $5.2 million, or $0.02 and $0.04 per share for the three months and year ended December 31, 2025, respectively. The Company recorded restructuring and asset write-off charges (gains) of $3.8 million in Cost of goods sold during the three months and year ended December 31, 2024, and ($22.2) million and net charges of $1.2 billion during the three months and year ended December 31, 2024, respectively in Restructuring charges and asset write-offs. In addition, losses of $4.6 million and $26.1 million were recorded in Other (expenses) income, net for the three months and year ended December 31, 2024, respectively, related to these actions. In total, this resulted in after-tax (gains) losses of ($24.9) million and $1.1 billion, or ($0.21) and $9.77 per share for the three months and year ended December 31, 2024, respectively. The tax impact includes a valuation allowance to reverse the tax benefits associated with the expenses recorded in Australia.







    (2)



    Non-cash goodwill impairment charge of $181.1 million ($181.1 million or $1.54 per share after income tax expense) recorded during the year ended December 31, 2025 related to our Refining Solutions business within our Ketjen reportable segment.







    (3)



    Non-cash long-lived asset impairment charge of $245.6 million ($245.6 million or $2.09 per share after income tax expense) recorded during the three months and year ended December 31, 2025 to reduce the carrying value of our Refining Solutions business to its fair value less costs to sell following classification as held for sale.







    (4)



    Costs related to the acquisition, integration and divestitures for various significant projects, recorded in Selling, general and administrative expenses for the three months and year ended December 31, 2025 were $3.2 million and $8.3 million ($4.3 million and $8.3 million after income taxes due to the impact of valuation allowances, or $0.04 and $0.07 per share), respectively, and for the three months and year ended December 31, 2024 were $2.3 million and $6.2 million ($1.8 million and $4.9 million after income taxes, or $0.01 and $0.04 per share), respectively.







    (5)



    Gains of $8.0 million and $11.1 million ($8.7 million and $11.1 million after income taxes due to the impact of valuation allowances, or $0.07 and $0.09 per share) recorded in Other (expenses) income, net resulting from the net change in fair value of investments in public equity securities for the three months and year ended December 31, 2025, respectively. Losses of $4.8 million and $37.0 million recorded in Other (expenses) income, net resulting from the net change in fair value of investments in public equity securities for the three months and year ended December 31, 2024, respectively, and a loss of $33.7 million recorded in Other (expenses) income, net for the year ended December 31, 2024 resulting from the sale of investments in public equity securities ($3.7 million and $62.7 million after income taxes, or $0.03 and $0.53 per share).







    (6)



    Included in Interest and financing expenses for the three months and year ended December 31, 2025 is a loss on early extinguishment of debt of $7.5 million ($0.06 per share, with no adjustment from income taxes due to the impact of valuation allowances), representing the unamortized discounts from the amendment of other debt.







    (7)



    Other adjustments for the three months ended December 31, 2025 included amounts recorded in:





    •

    Cost of goods sold - $4.8 million related to the write-off of assets damaged in a severe weather incident in Jordan.





    •

    Selling, general and administrative expenses - $9.2 million related to the write-off of assets damaged in a severe weather incident in Jordan and $0.8 million related to the write-off of certain fixed assets, partially offset by a $0.7 million gain resulting from the adjustment of severance expenses not related to a restructuring plan.





    •

    Other (expenses) income, net - $14.3 million loss related to the sale of our ownership interest in the Nippon Aluminum Alkyls joint venture.





    After income taxes, these net losses totaled $33.1 million, or $0.28 per share.











    Other adjustments for the year ended December 31, 2025 included amounts recorded in:





    •

    Cost of goods sold - $4.8 million related to the write-off of assets damaged in a severe weather incident in Jordan.





    •

    Selling, general and administrative expenses - $9.2 million related to the write-off of assets damaged in a severe weather incident in Jordan, $3.1 million of severance expenses not related to a restructuring plan, $2.2 million related to the write-off of certain fixed assets, $2.0 million of expenses related to certain historical legal matters and $1.4 million of expenses related to the redemption of preferred equity in a Grace subsidiary, partially offset by $13.3 million of gains from the sale of assets not part of our production operations.





    •

    Other (expenses) income, net - $38.0 million loss resulting from the redemption of preferred equity in a Grace subsidiary, $14.3 million loss related to the sale of our ownership interest in the Nippon Aluminum Alkyls joint venture and $1.9 million of charges for asset retirement obligations at a site not part of our operations, partially offset by $19.8 million of income from PIK dividends of the preferred equity in a Grace subsidiary prior to redemption and a $2.4 million gain primarily resulting from the adjustment of indemnification related to previously disposed businesses.





    After income taxes, these net losses totaled $41.5 million, or $0.35 per share.











    Other adjustments for the three months ended December 31, 2024 included amounts recorded in:





    •

    Other (expenses) income, net - $23.5 million of gains from the sale of assets at a site not part of our operations, $9.5 million of income from PIK dividends of preferred equity in a Grace subsidiary, a $1.4 million net gain primarily resulting from the adjustment of indemnification related to previously disposed businesses, partially offset by $2.1 million of a loss related to the fair value adjustment of a nonmarketable security investment.





    After income taxes, these net gains totaled $22.7 million, or $0.19 per share.











    Other adjustments for the year ended December 31, 2024 included amounts recorded in:





    •

    Cost of goods sold - $1.4 million of expenses related to non-routine labor and compensation related costs that are outside normal compensation arrangements.





    •

    Selling, general and administrative - $5.3 million of expenses related to certain historical legal and environmental matters.





    •

    Other (expenses) income, net - $40.9 million of gains from the sale of assets at sites not part of our operations, $36.3 million of income from PIK dividends of preferred equity in a Grace subsidiary, a $1.8 million net gain primarily resulting from the adjustment of indemnification related to previously disposed businesses and a $0.6 million gain from an updated cost estimate of an environmental reserve at a site not part of our operations, partially offset by $2.9 million of charges for asset retirement obligations at a site not part of our operations and $2.1 million of a loss related to the fair value adjustment of a nonmarketable security investment.





    After income taxes, these net gains totaled $49.0 million, or $0.42 per share.







    (8)



    Included in Income tax expense for the three months and year ended December 31, 2025 are discrete net tax expenses of $86.2 million, or $0.73 per share, and $88.1 million, or $0.75 per share, respectively, primarily related to a U.S. basis difference in Ketjen entities.











    Included in Income tax expense for the three months and year ended December 31, 2024 are discrete net tax benefits of $111.4 million, or $0.95 per share, and $117.5 million, or $1.00 per share, respectively, primarily related to the impact of valuation allowances on a return to provision, partially offset by the increase in a foreign tax reserve.

    See below for a reconciliation of the adjusted effective income tax rate, the non-GAAP financial measure, to the effective income tax rate, the most directly comparable financial measure calculated and reporting in accordance with GAAP (in thousands, except percentages).



    (Loss) income

    before income taxes

    and equity in net

    income of

    unconsolidated

    investments



    Income tax expense

    (benefit)



    Effective income

    tax rate

    Three months ended December 31, 2025:











    As reported

    $                   (284,990)



    $                    157,330



    (55.2) %

    Non-recurring, other unusual and non-operating pension and OPEB items

    295,527



    (98,208)





    As adjusted

    $                      10,537



    $                      59,122



    561.1 %













    Three months ended December 31, 2024:











    As reported

    $                      76,727



    $                      10,613



    13.8 %

    Non-recurring, other unusual and non-operating pension and OPEB items

    (49,232)



    112,272





    As adjusted

    $                      27,495



    $                    122,885



    446.9 %













    Year ended December 31, 2025:











    As reported

    $                   (552,073)



    $                    156,881



    (28.4) %

    Non-recurring, other unusual and non-operating pension and OPEB items

    498,332



    (86,419)





    As adjusted

    $                     (53,741)



    $                      70,462



    (131.1) %













    Year ended December 31, 2024:











    As reported

    $                (1,763,825)



    $                      87,085



    (4.9) %

    Non-recurring, other unusual and non-operating pension and OPEB items

    1,178,692



    137,914





    As adjusted

    $                   (585,133)



    $                    224,999



    (38.5) %

    See below for the calculation of operating cash flow conversion and a reconciliation of free cash flow, a non-GAAP measure, to net cash provided by operating activities, the most directly comparable financial measure calculated and reporting in accordance with GAAP. The Company defines as Net cash provided by operating activities from the statement of cash flows divided by adjusted EBITDA, which is a non-GAAP measure. A reconciliation of adjusted EBITDA, the non-GAAP financial measure, from net income (loss) attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reporting in accordance with GAAP, is provided in the above tables (in thousands, except percentages).



    Year Ended



    December 31, 2025

    Free cash flow:



    Net cash provided by operating activities

    $            1,282,267

    Less: Capital expenditures

    (589,801)

    Free cash flow

    $               692,466





    Operating cash flow conversion:



    Net cash provided by operating activities

    $            1,282,267





    Adjusted EBITDA

    $            1,097,993





    Operating cash flow conversion

    117 %

     

    Albemarle Investor Relations Contact: +1 (980) 308-6194, [email protected] 

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/albemarle-reports-fourth-quarter-and-full-year-2025-results-302685449.html

    SOURCE Albemarle Corporation

    Get the next $ALB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALB

    DatePrice TargetRatingAnalyst
    1/21/2026$205.00Hold → Buy
    Truist
    1/20/2026$200.00Hold → Buy
    HSBC Securities
    1/13/2026$185.00Hold → Buy
    Deutsche Bank
    1/12/2026$200.00Sector Perform → Sector Outperform
    Scotiabank
    1/7/2026$210.00Neutral → Outperform
    Robert W. Baird
    12/16/2025$147.00Underweight → Equal-Weight
    Morgan Stanley
    12/5/2025$185.00Neutral → Buy
    UBS
    12/2/2025$113.00Underperform → Neutral
    Robert W. Baird
    More analyst ratings

    $ALB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Albemarle Announces Plans to Idle its Kemerton Lithium Hydroxide Processing Plant

    Decision improves financial flexibility and preserves optionality CHARLOTTE, N.C., Feb. 11, 2026 /PRNewswire/ -- Albemarle Corporation (NYSE:ALB), a global leader in providing essential elements for mobility, energy, connectivity and health, today announced it will idle the remaining operating train, Train 1, at its Kemerton lithium hydroxide processing plant in Western Australia and place it into care and maintenance effective immediately. Today's announcement follows actions in 2024 to place Train 2 into care and maintenance and to cease expansion plans for Trains 3 and 4.

    2/11/26 4:20:00 PM ET
    $ALB
    Major Chemicals
    Industrials

    Albemarle Reports Fourth Quarter and Full Year 2025 Results

    CHARLOTTE, N.C., Feb. 11, 2026 /PRNewswire/ -- Albemarle Corporation (NYSE:ALB), a global leader in providing essential elements for mobility, energy, connectivity and health, today announced its results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Results and Highlights(Unless otherwise stated, all percentage changes represent year-over-year comparisons) Fourth quarter net sales of $1.4 billion, up 16%; volume up 12%, including gains in all segments led by Energy Storage (up 17%) and Ketjen (up 13%).Fourth quarter net loss of

    2/11/26 4:15:00 PM ET
    $ALB
    Major Chemicals
    Industrials

    Lithium Reclaims Its Role as a Critical Growth Metal as Miners Ramp Up Operations in 2026

    NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - Lithium demand is picking up real momentum as electric vehicles and energy storage continue to scale globally. EVs remain the biggest driver, but what's changing the story is how quickly battery storage for power grids, renewables, and data centers is growing. As governments and utilities push for more reliable, low-carbon power, lithium-based batteries are becoming essential infrastructure. Industry forecasts continue to point to lithium demand more than doubling by the end of the decade, with 2026 shaping up as a key inflection year where demand growth clearly outpaces new supply. Active Companies the marke

    1/15/26 8:45:00 AM ET
    $ALB
    $LAC
    $SLI
    Major Chemicals
    Industrials
    Metal Mining
    Basic Materials

    $ALB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Albemarle upgraded by Truist with a new price target

    Truist upgraded Albemarle from Hold to Buy and set a new price target of $205.00

    1/21/26 8:25:13 AM ET
    $ALB
    Major Chemicals
    Industrials

    Albemarle upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Albemarle from Hold to Buy and set a new price target of $200.00

    1/20/26 8:06:42 AM ET
    $ALB
    Major Chemicals
    Industrials

    Albemarle upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Albemarle from Hold to Buy and set a new price target of $185.00

    1/13/26 8:40:16 AM ET
    $ALB
    Major Chemicals
    Industrials

    $ALB
    SEC Filings

    View All

    SEC Form 10-K filed by Albemarle Corporation

    10-K - ALBEMARLE CORP (0000915913) (Filer)

    2/11/26 4:49:08 PM ET
    $ALB
    Major Chemicals
    Industrials

    Albemarle Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ALBEMARLE CORP (0000915913) (Filer)

    2/11/26 4:23:21 PM ET
    $ALB
    Major Chemicals
    Industrials

    Amendment: SEC Form SCHEDULE 13G/A filed by Albemarle Corporation

    SCHEDULE 13G/A - ALBEMARLE CORP (0000915913) (Subject)

    1/29/26 11:23:22 AM ET
    $ALB
    Major Chemicals
    Industrials

    $ALB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO Masters J Kent covered exercise/tax liability with 27,459 shares, decreasing direct ownership by 19% to 118,853 units (SEC Form 4)

    4 - ALBEMARLE CORP (0000915913) (Issuer)

    1/2/26 4:13:08 PM ET
    $ALB
    Major Chemicals
    Industrials

    Chief Financial Officer Sheorey Neal Ravi covered exercise/tax liability with 854 shares and converted options into 1,953 shares, increasing direct ownership by 10% to 12,210 units (SEC Form 4)

    4 - ALBEMARLE CORP (0000915913) (Issuer)

    11/10/25 4:13:38 PM ET
    $ALB
    Major Chemicals
    Industrials

    General Counsel & Sec Krupa Ander C. sold $18,060 worth of shares (172 units at $105.00), decreasing direct ownership by 1% to 11,483 units (SEC Form 4)

    4 - ALBEMARLE CORP (0000915913) (Issuer)

    10/28/25 4:17:35 PM ET
    $ALB
    Major Chemicals
    Industrials

    $ALB
    Leadership Updates

    Live Leadership Updates

    View All

    Ketjen Announces the Appointment of Henri Tausch as Chief Commercial Officer

    Ketjen Corporation, a leader in catalyst and specialty chemicals manufacturing, today announces the appointment of Henri Tausch to Chief Commercial Officer (CCO) effective June 24, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240619765799/en/Henri Tausch, Ketjen Chief Commercial Officer (Photo: Business Wire) In his role as Chief Commercial Officer, Tausch will oversee and advance the company's commercial strategy, and foster key partnerships to accelerate the company's global growth trajectory. "I am honored to join Ketjen and contribute to its continued success," said Henri Tausch "It's inspiring to see Ketjen's dedi

    6/19/24 7:00:00 AM ET
    $ALB
    Major Chemicals
    Industrials

    International Paper Announces Changes to Its Board of Directors

     Jamie A. Beggs and Scott A. Tozier to Join as Newest Board Members Ilene S. Gordon to Retire from the Board MEMPHIS, Tenn., May 22, 2024 /PRNewswire/ -- International Paper ("IP") (NYSE:IP) announced that Jamie A. Beggs and Scott A. Tozier have been elected to IP's Board of Directors, effective May 21, 2024. The company also announced that Ilene S. Gordon has retired from the Board citing personal and health reasons, effective May 21, 2024. Ms. Beggs, age 47, currently serves as Senior Vice President and Chief Financial Officer of Avient Corporation (NYSE:AVNT), a premier pr

    5/23/24 10:51:00 AM ET
    $ALB
    $AVNT
    $IP
    Major Chemicals
    Industrials
    Paper
    Basic Materials

    Albemarle Reports Net Sales Increase of 60% for Second Quarter 2023

    CHARLOTTE, N.C., Aug. 2, 2023 /PRNewswire/ -- Albemarle Corporation (NYSE:ALB), a global leader in providing essential elements for mobility, energy, connectivity and health, today announced its results for the second quarter ended June 30, 2023. Second-Quarter 2023 and Recent Highlights(Unless otherwise stated, all percentage changes represent year-over-year comparisons) Net sales of $2.4 billion, an increase of 60%Net income of $650.0 million, or $5.52 per diluted share, an increase of 60%Adjusted diluted EPS of $7.33, an increase of 112%Adjusted EBITDA of $1.0 billion, an i

    8/2/23 4:15:00 PM ET
    $ALB
    Major Chemicals
    Industrials

    $ALB
    Financials

    Live finance-specific insights

    View All

    Albemarle Announces Plans to Idle its Kemerton Lithium Hydroxide Processing Plant

    Decision improves financial flexibility and preserves optionality CHARLOTTE, N.C., Feb. 11, 2026 /PRNewswire/ -- Albemarle Corporation (NYSE:ALB), a global leader in providing essential elements for mobility, energy, connectivity and health, today announced it will idle the remaining operating train, Train 1, at its Kemerton lithium hydroxide processing plant in Western Australia and place it into care and maintenance effective immediately. Today's announcement follows actions in 2024 to place Train 2 into care and maintenance and to cease expansion plans for Trains 3 and 4.

    2/11/26 4:20:00 PM ET
    $ALB
    Major Chemicals
    Industrials

    Albemarle Reports Fourth Quarter and Full Year 2025 Results

    CHARLOTTE, N.C., Feb. 11, 2026 /PRNewswire/ -- Albemarle Corporation (NYSE:ALB), a global leader in providing essential elements for mobility, energy, connectivity and health, today announced its results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Results and Highlights(Unless otherwise stated, all percentage changes represent year-over-year comparisons) Fourth quarter net sales of $1.4 billion, up 16%; volume up 12%, including gains in all segments led by Energy Storage (up 17%) and Ketjen (up 13%).Fourth quarter net loss of

    2/11/26 4:15:00 PM ET
    $ALB
    Major Chemicals
    Industrials

    Albemarle Corporation to Release Fourth Quarter 2025 Earnings Results on Wednesday, February 11, 2026

    CHARLOTTE, N.C., Jan. 13, 2026 /PRNewswire/ -- Albemarle Corporation (NYSE:ALB), a global leader in providing essential elements for mobility, energy, connectivity and health, announced today that it will release its fourth quarter 2025 earnings after the NYSE closes on Wednesday, February 11, 2026. The company will hold a conference call to discuss its fourth quarter 2025 results on Thursday, February 12, at 8 a.m. EST. Access to the call is available via webcast or direct dial. A link to the webcast can be found through Albemarle Corporation's website at http://investors.alb

    1/13/26 4:15:00 PM ET
    $ALB
    Major Chemicals
    Industrials

    $ALB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Albemarle Corporation

    SC 13G/A - ALBEMARLE CORP (0000915913) (Subject)

    12/5/24 7:27:01 PM ET
    $ALB
    Major Chemicals
    Industrials

    SEC Form SC 13G filed by Albemarle Corporation

    SC 13G - ALBEMARLE CORP (0000915913) (Subject)

    11/13/24 12:52:42 PM ET
    $ALB
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Albemarle Corporation

    SC 13G/A - ALBEMARLE CORP (0000915913) (Subject)

    11/13/24 10:27:59 AM ET
    $ALB
    Major Chemicals
    Industrials

    $ALB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Coleman Kristin M. bought $167,314 worth of shares (1,373 units at $121.86) (SEC Form 4)

    4 - ALBEMARLE CORP (0000915913) (Issuer)

    11/7/23 4:39:49 PM ET
    $ALB
    Major Chemicals
    Industrials